Will Cost Control Help Teva (TEVA) Beat On Q2 Earnings?
Zacks Investment Research | Aug 04, 2019 09:07PM ET
We expect Teva Pharmaceutical Industries Limited (NYSE:TEVA) to beat estimates when it reports second-quarter 2019 results on Aug 7, before market open. In the last reported quarter, the company delivered a positive earnings surprise of 3.45%.
Teva’s earnings surpassed expectations in three the last four reported quarters, with the average positive surprise being 9.54%.
Teva Pharmaceutical Industries Ltd. Price and Consensus
Teva Pharmaceutical Industries Ltd. Quote
This generic drugmaker’s shares have declined 49% this year so far compared with the industry ’s decline of 4.7%.
Let’s see how things are shaping up for this announcement.
Factors to Consider
Teva reports under three segments based on three regions — North America (United States and Canada), Europe and International Markets.
In the second quarter, pricing erosion in the U.S. generics market, continued sales erosion of Copaxone due to introduction of generics and lower sales of other branded drugs Bendeka, Treanda, ProAir and Qvar will continue to hurt North America segment sales. Particularly, ProAir sales are likely to be hurt by the launch of a generic version of the drug. In Europe as well as International Markets segments, loss of revenues from divestitures and discontinued business activities is likely to hurt sales. The decline in sales of generic medicines and Copaxone is expected to continue, which can offset the positive impact of generic launches.
Additional competition for Teva’s largest product, Concerta authorized generic, will also hurt generics sales in the quarter. However, on the first-quarter conference call, the company had noted signs of stabilization in the US generics and European generics business helped by launches and strong key products. Revenues lost due to price erosion in the U.S generics business and portfolio optimization were partially offset by additional sales from the launch of generic products. We can expect a similar trend in the to-be-reported quarter.
Generic launches in the second quarter include that of Gilead’s (NASDAQ:GILD) Letairis, Roche’s Tarceva and Allergan’s (NYSE:AGN) Delzicol in May. In March/April, Teva launched generic versions of VESIcare (solifenacin succinate) tablets and AndroGel (testosterone gel) and Exjade tablets and an authorized generic version of Flector patch, a nonsteroidal anti-inflammatory medicine to treat acute pain.
Its new drugs, Austedo and Ajovy should contribute to the top line. Importantly, Ajovy was approved in the EU in April, which should add to sales in the second quarter. Investors will also be interested to know how management plans to capture market share for Ajovy against Amgen (NASDAQ:AMGN) and Lilly’s CGRP’s, which were also launched last year.
Research and development costs could be lower due to pipeline optimization, concluded phase III studies and resultant workforce reductions. Also, cost cutting and re-structuring activities should result in lower selling and marketing expenditure.
In April, Teva announced the discontinuation of a late-stage study evaluating Ajovy for episodic cluster headache. Investors are expected to question management on the issue on the second-quarter conference call. In June 2018, Teva had stopped a study on the same candidate for chronic cluster headache.
Earnings Whispers
Our proven model shows that Teva is likely to beat estimates this quarter because it has the right combination of two key ingredients. A stock needs to have both a positive Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.